17-Apr-2026
Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference
Business Wire (Wed, 4-Mar 4:05 PM ET)
Business Wire (Wed, 25-Feb 7:05 AM ET)
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Investor Update Call
Business Wire (Wed, 18-Feb 4:21 PM ET)
Market Chameleon (Fri, 2-Jan 4:53 AM ET)
Market Chameleon (Fri, 2-Jan 2:59 AM ET)
Market Chameleon (Mon, 10-Nov 5:33 AM ET)
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
Ironwood Pharmaceuticals - Class A trades on the NASDAQ stock market under the symbol IRWD.
As of April 17, 2026, IRWD stock price climbed to $4.43 with 1,898,338 million shares trading.
IRWD has a beta of -0.03, meaning it tends to be less sensitive to market movements. IRWD has a correlation of 0.00 to the broad based SPY ETF.
IRWD has a market cap of $720.67 million. This is considered a Small Cap stock.
Last quarter Ironwood Pharmaceuticals - Class A reported $48 million in Revenue and -$.01 earnings per share. This fell short of revenue expectation by $-4 million and missed earnings estimates by -$.02.
In the last 3 years, IRWD traded as high as $15.70 and as low as $.53.
The top ETF exchange traded funds that IRWD belongs to (by Net Assets): XBI, IWM, VTI, FNDA, VXF.
IRWD has outperformed the market in the last year with a price return of +509.6% while the SPY ETF gained +36.3%. However, in the short term, IRWD had mixed performance relative to the market. It has underperformed in the last 3 months, returning -1.6% vs +2.9% return in SPY. But in the last 2 weeks, IRWD shares have fared better than the market returning +25.1% compared to SPY +8.3%.
IRWD support price is $4.10 and resistance is $4.56 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IRWD shares will trade within this expected range on the day.
